



Pemetrexed (Alimta®)

DESCRIPTION

Pemetrexed is a folate analog metabolic inhibitor. It interferes with cell metabolic processes by disrupting the folate-dependent processes required for cell replication by inhibiting the biosynthesis of thymidine and purine nucleotides. This prevents the formation of the DNA and RNA required for the growth and survival of both cancer and normal cells.

POLICY

- Pemetrexed for the treatment of the following is considered **medically necessary** if the medical appropriateness criteria are met: **(See Medical Appropriateness below.)**
 - Primary Central Nervous System (CNS) Lymphoma
 - Malignant Pleural Mesothelioma
 - Non-Squamous Non-Small Cell Lung Cancer
 - Thymomas and thymic carcinomas
 - Ovarian Cancer
- Pemetrexed for the treatment of other conditions/diseases is considered **investigational**.

MEDICAL APPROPRIATENESS

The proposal is to add text/statements in red and to delete text/statements with strikethrough:

INITIAL APPROVAL CRITERIA

- Patient is at least 18 years of age; **AND**

Primary Central Nervous System (CNS) Lymphoma

- Used as a single agent as induction therapy in patients unsuitable for or intolerant to high-dose methotrexate (MTX); **OR**
- Used as single agent therapy for relapsed or refractory disease; **AND**
 - Patient received prior whole brain radiation therapy (RT); **OR**
 - Patient received a prior high-dose MTX-based regimen without prior radiation therapy; **OR**
 - Used in combination with whole brain RT or involved field RT in patients who received a prior high-dose MTX-based regimen without prior RT with either no response or short response (<12 month duration) to prior regimen; **OR**
 - Patient received prior high-dose chemotherapy with stem cell rescue

Malignant Pleural* Mesothelioma (MPM)

- Used in combination with cisplatin or carboplatin; **AND**
 - Patient has stage IIIB or IV disease, sarcomatoid, or medically inoperable tumors and used as initial first-line therapy with or without bevacizumab; **OR**
 - Patient has stage I-III A disease with epithelioid or biphasic histology; **AND**
 - Used as induction therapy; **OR**
 - Used as first-line therapy with or without bevacizumab for unresectable disease; **OR**
 - Used as first-line therapy for resected disease not previously treated with induction chemotherapy; **OR**
- Used as a single agent; **AND**
 - Patient has stage IIIB or IV disease, sarcomatoid, or medically inoperable tumors and used as first-line therapy; **OR**



Medical Policy Manual

Draft Revised Policy: Do Not Implement

- Patient has stage I-IIIa disease with epithelioid or biphasic histology; **AND**
 - Used as first-line therapy for unresectable disease; **OR**
 - Used as first-line therapy for resected disease not previously treated with induction chemotherapy; **OR**
- Used as subsequent therapy, if not administered first-line; **OR**
- Used as a re-challenge, if pemetrexed was administered first-line with a good sustained response at the time initial chemotherapy was interrupted;

**peritoneal, pericardial, and tunica vaginalis testis mesothelioma will be evaluated on a case-by-case basis*

Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC)

- Used in combination with carboplatin or cisplatin; **AND**
 - Used as induction, neoadjuvant, or adjuvant therapy; **OR**
 - Used as concurrent chemoradiation for locoregional recurrence or symptomatic local disease in the mediastinal lymph nodes or for superior vena cava obstruction; **OR**
 - Used as initial therapy as definitive concurrent chemoradiation for unresectable, advanced, or metastatic disease; **OR**
- Used for recurrent, advanced, or metastatic disease (excluding locoregional recurrence or symptomatic local disease without evidence of disseminated disease) or mediastinal lymph node recurrence with prior radiation therapy; **AND**
 - Used as first-line therapy; **AND**
 - Used for PD-L1 $\geq 1\%$ tumors that **have negative actionable molecular markers*** ~~are EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping mutation, and RET rearrangement negative*~~; **AND**
 - Used in combination with pembrolizumab and either carboplatin or cisplatin in patients with PS 0-2; **OR**
 - Used in combination with nivolumab, ipilimumab, and either carboplatin or cisplatin in patients with PS 0-2; **OR**
 - Used for one of the following:
 - PD-L1 $< 1\%$ and **tumors that have negative actionable molecular markers*** ~~EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping mutation, and RET rearrangement negative*~~ tumors
 - BRAF V600E-mutation, NTRK 1/2/3 gene fusion **or** MET exon-14 skipping mutation, ~~or RET rearrangement positive tumors~~; **AND**
 - Used as a single agent in patients with PS 2; **OR**
 - Used in combination with pembrolizumab and either carboplatin or cisplatin in patients with PS 0-1 (*excluding use in patients who have received prior PD-1/PD-L1 inhibitor therapy or who have RET rearrangement positive tumors*); **OR**
 - Used in combination with cisplatin in patients with PS 0-1; **OR**
 - Used in combination with carboplatin in patients with PS 0-2; **OR**
 - Used in combination with nivolumab, ipilimumab, and either carboplatin or cisplatin in patients with PS 0-1; **OR**
 - Used in combination with bevacizumab and either cisplatin or carboplatin in patients with PS 0-1 (*excluding use in patients who have received prior PD-1/PD-L1 inhibitor therapy or who have RET rearrangement positive tumors*); **OR**
 - Used as subsequent therapy; **AND**
 - Used as a single-agent (if not previously given) in patients with a PS 0-2; **OR**
 - Used for one of the following:
 - EGFR, ALK, or ROS1 positive tumors and prior targeted therapy§ for those aberrations
 - BRAF V600E-mutation, NTRK1/2/3 gene fusion **or** MET exon-14 skipping mutation, ~~or RET rearrangement positive tumors~~
 - PD-L1 $\geq 1\%$ tumors that **have negative actionable molecular markers*** ~~are EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping mutation, and RET rearrangement~~



- negative* with prior PD- 1/PD-L1 inhibitor therapy but no prior platinum doublet chemotherapy; **AND**
- Used in combination with pembrolizumab and either carboplatin or cisplatin in patients with PS 0-1 (~~excluding use in patients who have received prior PD-1/PD-L1 inhibitor therapy or who have EGFR, ALK, and RET rearrangement positive tumors~~); **OR**
 - Used in combination with cisplatin in patients with PS 0-1; **OR**
 - Used in combination with carboplatin in patients with PS 0-2; **OR**
 - Used in combination with nivolumab, ipilimumab, and either carboplatin or cisplatin in patients with PS 0-1 (~~excluding use in patients who have received prior PD-1/PD-L1 inhibitor therapy or who have EGFR, ALK, and RET rearrangement positive tumors~~); **OR**
 - Used in combination with bevacizumab and either cisplatin or carboplatin in patients with PS 0-1; **OR**
- Used as maintenance therapy in patients who have achieved tumor response or stable disease following initial therapy; **AND**
 - Used as a single agent for continuation maintenance therapy; **OR**
 - Used as a single agent for switch maintenance therapy; **OR**
 - Used for continuation maintenance therapy in combination with bevacizumab following a first-line bevacizumab/pemetrexed/platinum chemotherapy regimen; **OR**
 - Used for continuation maintenance therapy in combination with pembrolizumab following a first-line pembrolizumab/pemetrexed and either carboplatin or cisplatin regimen

** Note: Actionable molecular genomic biomarkers include EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping mutation, and RET rearrangement. If there is insufficient tissue to allow testing for all of the EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET, and RET, repeat biopsy and/or plasma testing should be done. If these are not feasible, treatment is guided by available results and, if unknown, these patients are treated as though they do not have driver oncogenes.*

Note: Contraindications for treatment with PD-1/PD-L1 inhibitors may include active or previously documented auto-immune disease and/or current use of immunosuppressive agents, or presence of an oncogene (e.g., EGFR [exon 19 deletions, p.L858R point mutation in exon 21], ALK rearrangements, RET rearrangements), which would predict lack of benefit.

Thymomas/Thymic Carcinoma

- Used as a single agent; **AND**
 - Used, as first line therapy or postoperative treatment, in patients who are unable to tolerate first-line combination regimens; **OR**
 - Used as second-line therapy for unresectable or metastatic disease

Ovarian Cancer (epithelial ovarian/fallopian tube/primary peritoneal cancer)

- Patient has recurrent or persistent disease; **AND**
- Patient is not experiencing an immediate biochemical relapse (i.e., rising CA-125 without radiographic evidence of disease); **AND**
- Used as a single agent; **AND**
 - Patient has platinum-resistant disease; **AND**
 - Used for progression on primary, maintenance, or recurrence therapy; **OR**
 - Used for stable or persistent disease if not currently on maintenance therapy; **OR**
 - Used for relapsed disease <6 months following complete remission from prior chemotherapy; **OR**
 - Patient has platinum-sensitive disease; **AND**



- Used for radiographic and/or clinical relapse \geq 6 months after complete remission from prior chemotherapy

Genomic Aberration/Mutational Driver Targeted Therapies (Note: <i>not all inclusive, refer to guidelines for appropriate use</i>) §				
Sensitizing <i>EGFR</i> mutation-positive tumors	<i>ALK</i> rearrangement-positive tumors	<i>ROS1</i> rearrangement positive tumors	<i>BRAF</i> V600E-mutation positive tumors	<i>NTRK</i> Gene Fusion positive tumors
<ul style="list-style-type: none"> - Afatinib - Erlotinib - Dacomitinib - Gefitinib - Osimertinib - Amivantamab (exon-20 insertion) 	<ul style="list-style-type: none"> - Alectinib - Brigatinib - Ceritinib - Crizotinib - Lorlatinib 	<ul style="list-style-type: none"> - Ceritinib - Crizotinib - Entrectinib 	<ul style="list-style-type: none"> - Dabrafenib \pm Trametinib - Vemurafenib 	<ul style="list-style-type: none"> - Larotrectinib - Entrectinib
PD-1/PD-L1 expression positive tumors (\geq 1%)	<i>MET</i> Exon-14 skipping mutations	<i>RET</i> rearrangement positive tumors	<i>KRAS</i> G12C mutations	
<ul style="list-style-type: none"> - Pembrolizumab - Atezolizumab - Nivolumab \pm Ipilimumab 	<ul style="list-style-type: none"> - Capmatinib - Crizotinib - Tepotinib 	<ul style="list-style-type: none"> - Selpercatinib - Cabozantinib - Vandetanib - Pralsetinib 	<ul style="list-style-type: none"> - Sotorasib 	

§Genomic Aberration/Mutational Driver Targeted Therapies (Note: <i>not all inclusive, refer to guidelines for appropriate use</i>)
<p>Sensitizing <i>EGFR</i> mutation-positive tumors</p> <ul style="list-style-type: none"> ☐ Afatinib ☐ Erlotinib ☐ Dacomitinib ☐ Gefitinib ☐ Osimertinib
<p><i>ALK</i> rearrangement-positive tumors</p> <ul style="list-style-type: none"> ☐ Alectinib ☐ Brigatinib ☐ Ceritinib ☐ Crizotinib ☐ Lorlatinib
<p><i>ROS1</i> rearrangement-positive tumors</p> <ul style="list-style-type: none"> ☐ Ceritinib ☐ Crizotinib ☐ Entrectinib
<p><i>BRAF</i> V600E-mutation positive tumors</p> <ul style="list-style-type: none"> ☐ Dabrafenib \pm Trametinib ☐ Vemurafenib
<p><i>NTRK</i> Gene Fusion-positive tumors</p> <ul style="list-style-type: none"> ☐ Larotrectinib ☐ Entrectinib



<p>PD-1/PD-L1 expression-positive tumors (≥1%)</p> <ul style="list-style-type: none"> ☐ Pembrolizumab ☐ Atezolizumab ☐ Nivolumab ± ipilimumab
<p><i>MET</i> Exon-14 skipping mutations</p> <ul style="list-style-type: none"> ☐ Capmatinib ☐ Crizotinib ☐ Tepotinib
<p><i>RET</i> rearrangement-positive tumors</p> <ul style="list-style-type: none"> ☐ Selpercatinib ☐ Cabozantinib ☐ Vandetanib ☐ Pralsetinib

RENEWAL CRITERIA

- Patient continues to meet indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in initial criteria; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: bone marrow suppression (e.g., neutropenia, febrile neutropenia, thrombocytopenia, anemia), renal impairment (CrCl < 45 mL/min), bullous and exfoliative skin toxicity (e.g., Stevens-Johnson Syndrome/Toxic epidermal necrolysis), interstitial pneumonitis, radiation recall, etc.; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**

Continuation of Maintenance Therapy for Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

- Refer to the Initial Approval Criteria

MPM

- May not be renewed when used in combination with platinum therapy and bevacizumab

Thymomas/Thymic Carcinoma

- May not be renewed

DOSAGE/ADMINISTRATION

INDICATION	DOSE
Non-Squamous NSCLC	Administer 500 mg/m ² intravenously every 21 days, until disease progression or unacceptable toxicity
Malignant Pleural Mesothelioma	Administer 500 mg/m ² intravenously every 21 days <ul style="list-style-type: none"> ☐ For 6 cycles only when used in combination with platinum therapy and bevacizumab ☐ All others until disease progression or unacceptable toxicity
Primary CNS Lymphoma, Ovarian Cancer	Administer 900 mg/m ² intravenously every 21 days, until disease progression or unacceptable toxicity



Medical Policy Manual

Draft Revised Policy: Do Not Implement

Thymomas/Thymic Carcinoma	Administer 500 mg/m ² intravenously every 21 days for a maximum of 6 cycles in absence of disease progression or unacceptable toxicity
<ul style="list-style-type: none"> • Supplement with oral folic acid and intramuscular vitamin B₁₂ • Avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration in patients with CrCl <80 mL/min. • Do not dose in patients with CrCl <45 mL/min 	

LENGTH OF AUTHORIZATION

Coverage will be provided for six months and may be renewed unless otherwise specified.

- Thymomas/Thymic Carcinoma: Coverage will be provided for six 21-day cycles and may not be renewed.
- MPM: Coverage will be provided for six 21-day cycles and may not be renewed when used in combination with platinum therapy and bevacizumab.

DOSAGE LIMITS

Max Units (per dose and over time) [HCPCS Unit]:

- CNS Lymphoma and Ovarian Cancer: 230 billable units every 21 days
- All other indications: 130 billable units every 21 days

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

SOURCES

1. Alimta [package insert]. Indianapolis, IN; Eli Lilly; January 2019. Accessed August 2021.
2. Pemfexy [package insert]. Woodcliff Lake, NJ; Eagle Pharmaceuticals, Inc.; May 2020. Accessed August 2021.

Medical Policy Manual

Draft Revised Policy: Do Not Implement

3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for pemetrexed. National Comprehensive Cancer Network, 2021. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed August 2021.
4. Castagneto B, Botta M, Aitini E, et al, "Phase II Study of Pemetrexed in Combination With Carboplatin in Patients With Malignant Pleural Mesothelioma (MPM)," *Ann Oncol*, 2008, 19(2):370-3.
5. Ceresoli GL, Zucali PA, Favaretto AG, et al, "Phase II Study of Pemetrexed plus Carboplatin in Malignant Pleural Mesothelioma," *J Clin Oncol*, 2006, 24(9):1443-8.
6. Taylor P, Castagneto B, Dark G, et al, "Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients With Malignant Pleural Mesothelioma: Results of an International Expanded Access Program," *J Thorac Oncol*, 2008, 3(7):764-71
7. Ciuleanu T, Brodowicz T, Zielinski C, et al, "Maintenance Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care for Non-Small-Cell Lung Cancer: A Randomised, Double-Blind, Phase 3 Study," *Lancet*, 2009, 374(9699):1432-40.
8. Grønberg BH, Bremnes RM, Fløtten O, et al, "Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer," *J Clin Oncol*, 2009, 27(19):3217-24.
9. Hanna N, Shepherd FA, Fossella FV, et al, "Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy," *J Clin Oncol*, 2004, 22(9):1589-97.
10. Jassem J, Ramlau R, Santoro A, et al, "Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma," *J Clin Oncol*, 2008, 26(10):1698-704.
11. Scagliotti GV, Parikh P, von Pawel J, et al, "Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve Patients With Advanced-Stage Non-Small-Cell Lung Cancer," *J Clin Oncol*, 2008, 26(21):3543-51.
12. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *Lancet Oncol*. 2016;17(11):1497-1508.
13. Miller DS, Blessing JA, Krasner CN, et al. Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. *J Clin Oncol*, 2009, 27(16):2686-91.
14. Liang Y, Padda SK, Riess JW, et al. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. *Lung Cancer*. 2015 Jan;87(1):34-8.
15. Gbolahan OB, Porter RF, Salter JT, et al. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma. *J Thorac Oncol*. 2018 Dec;13(12):1940-1948.
16. Raizer JJ, Rademaker A, Evens AM, et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. *Cancer*. 2012 Aug 1;118(15):3743-8.
17. Fahrenbruch R, Kintzel P, Bott AM, et al. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. *J Oncol Pract*. 2018 Mar;14(3):e130-e136.
18. Hematology/Oncology Pharmacy Association (2019). Intravenous Cancer Drug Waste Issue Brief. Retrieved from http://www.hoparx.org/images/hopa/advocacy/Issue_Briefs/Drug_Waste_2019.pdf
19. Bach PB, Conti RM, Muller RJ, et al. Overspending driven by oversized single dose vials of cancer drugs. *BMJ*. 2016 Feb 29;352:i788.
20. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005.
21. Wu YL, Lu S, Cheng Y, et al. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer. *Lung Cancer*. 2014;85(3):401-407. doi:10.1016/j.lungcan.2014.07.007.

22. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. *Lancet Oncol.* 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3.
23. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol.* 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136.
24. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1.2021. National Comprehensive Cancer Network, 2021. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed **August** 2021.
25. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thymomas and Thymic Carcinomas Version 1.2021. National Comprehensive Cancer Network, 2020. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed **August** 2021.
26. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Malignant Pleural Mesothelioma Version 1.2021. National Comprehensive Cancer Network, 2021. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed **August** 2021.
27. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers Version 1.2021. National Comprehensive Cancer Network, 2021. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed **August** 2021.
28. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer Version 2.2021. National Comprehensive Cancer Network, 2021. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed **August** 2021.
29. Lexi-Comp Online. (2021, February). AHFS DI. *Pemetrexed*. Retrieved **September** 2021 from Lexi-Comp Online with AHFS.
30. MICROMEDEX Healthcare Series. Drugdex Drug Evaluations. (2021, **August**). *Pemetrexed*. Retrieved **September** 2021 from MICROMEDEX Healthcare Series.

EFFECTIVE DATE

ID_MRx